Table 4.

Proposed development of GSH-based/redox therapeutics for chronic lung diseases.

•Develop a variant of GLRX for the treatment of IPF and COPD

•Repurpose TLK199 for the treatment of IPF

•PDI inhibitors for the treatment of asthma, COPD and IPF

•NOX4 inhibitors for the treatment of IPF

•DUOX1 inhibitors for the treatment of asthma

Note: TLK199 and TUCDA have already been used clinically, but the undesirable intellectual property domain along with concerns for future profit margins makes it unattractive to invest in costly clinical trials and re-development of these compounds.